Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director George M. Milne, Jr. Acquires 100,000 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director George M. Milne, Jr. purchased 100,000 shares of the firm’s stock in a transaction on Tuesday, September 3rd. The shares were acquired at an average cost of $2.20 per share, with a total value of $220,000.00. Following the completion of the acquisition, the director now directly owns 858,571 shares in the company, valued at $1,888,856.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Amylyx Pharmaceuticals Stock Up 7.7 %

Shares of AMLX stock opened at $2.37 on Friday. The stock has a market capitalization of $161.17 million, a PE ratio of -2.21 and a beta of -0.62. Amylyx Pharmaceuticals, Inc. has a 52-week low of $1.58 and a 52-week high of $21.28. The stock’s 50-day moving average price is $2.04 and its 200 day moving average price is $3.56.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.35). The company had revenue of ($1.02) million during the quarter, compared to analyst estimates of $18.83 million. Amylyx Pharmaceuticals had a negative net margin of 17.86% and a negative return on equity of 15.51%. During the same quarter last year, the firm earned $0.31 EPS. Analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.27 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC increased its position in Amylyx Pharmaceuticals by 52,575.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock valued at $43,000 after acquiring an additional 15,247 shares during the period. Algert Global LLC acquired a new position in Amylyx Pharmaceuticals in the 2nd quarter valued at about $47,000. CWM LLC increased its position in Amylyx Pharmaceuticals by 104.2% during the 2nd quarter. CWM LLC now owns 28,643 shares of the company’s stock worth $54,000 after purchasing an additional 14,613 shares during the period. Quest Partners LLC acquired a new position in Amylyx Pharmaceuticals during the 4th quarter worth approximately $89,000. Finally, SG Americas Securities LLC increased its position in Amylyx Pharmaceuticals by 113.6% during the 2nd quarter. SG Americas Securities LLC now owns 55,836 shares of the company’s stock worth $106,000 after purchasing an additional 29,697 shares during the period. Institutional investors and hedge funds own 95.84% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Amylyx Pharmaceuticals in a research report on Wednesday, July 10th. Mizuho cut their target price on Amylyx Pharmaceuticals from $4.00 to $3.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 14th. Finally, The Goldman Sachs Group lifted their target price on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a research report on Friday, July 12th. Six equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $17.60.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.